ClearPoint Neuro Inc. - Common Stock (NQ:CLPT)

10.69 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ClearPoint Neuro Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 29, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 28, 2024

Via Benzinga

Tech Trailblazers: 7 Small-Cap Stocks on the Verge of a Breakthrough ↗

February 28, 2024

These small-cap tech stocks are well on their way to a meteoric and historic rise, but it isn't too late to jump on the bandwagon.

Via InvestorPlace

The 3 Up-and-Coming Stocks That Could Make Your February Unforgettable ↗

February 15, 2024

Finding an up-and-coming stock worth investing in is harder than it used to be, but you don't have to look far if you check out this list.

Via InvestorPlace

ClearPoint Neuro: Q3 Earnings Insights ↗

November 09, 2023

Via Benzinga

ClearPoint Neuro: Q1 Earnings Insights ↗

May 11, 2023

Via Benzinga

Earnings Scheduled For March 1, 2023 ↗

March 01, 2023

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.

Via Benzinga

ClearPoint Neuro Secures FDA Nod For ClearPoint Prism Neuro Laser Therapy System ↗

September 23, 2022

Via Benzinga

The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn’t Ignore. ↗

February 15, 2024

Looking for the next generational winner in healthcare stocks? These are three of the top prospects today.

Via InvestorPlace

3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List ↗

February 09, 2024

These strong buy healthcare stocks are among analysts' favorite picks, and their strong market position tells us why.

Via InvestorPlace

3 Small-Cap Healthcare Stocks to Buy and Hold Forever: January 2024 ↗

January 25, 2024

Small-cap healthcare stocks combine relative cheapness with advanced innovations including AI, automation, and more.

Via InvestorPlace

Topics Artificial Intelligence

7 Small-Cap Stocks With Huge Potential Flying Under the Radar ↗

January 10, 2024

Small-cap stocks are massively undervalued and represent a unique investment opportunity for traders in 2024.

Via InvestorPlace

7 Solid Small-Caps for 2024 and Beyond ↗

December 05, 2023

Small-cap stocks are positioned to beat the biggest companies in 2024 as risk tolerance climbs and shares remain undervalued

Via InvestorPlace

FDA Approves ClearPoint Neuro's Updated Software For Guidance System For Neurological Procedures ↗

September 20, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023 ↗

October 24, 2023

Via Benzinga

Top 5 Health Care Stocks That Are Set To Fly In Q2 ↗

June 09, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

June 05, 2023

Monday's session saw 41 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 28, 2023

Friday's session saw 59 companies set new 52-week lows.

Via Benzinga

3 High-Potential Small-Cap Stocks for Investors With Strong Stomachs ↗

May 31, 2023

Small-cap stocks can be risky, and all three of these companies are facing adversity. But they could be home run investments.

Via InvestorPlace

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

May 24, 2023

From ClearPoint Neuro, Inc.

Via GlobeNewswire

3 Healthcare Stocks With Huge Growth Potential ↗

April 24, 2023

It's been a tough time for the tech industry. So consider these healthcare growth stocks to buy now instead.

Via InvestorPlace

ClearPoint Neuro's Earnings: A Preview ↗

November 07, 2022

ClearPoint Neuro (NASDAQ:CLPT) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that ClearPoint...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

October 18, 2022

It's time for another look at the biggest pre-market stock movers as we check out what's happening with shares on Tuesday morning!

Via InvestorPlace

ClearPoint Neuro: Q2 Earnings Insights ↗

August 09, 2022

ClearPoint Neuro (NASDAQ:CLPT) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings ClearPoint Neuro reported...

Via Benzinga

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 09, 2022

Via Benzinga

ClearPoint Shares Climb as FDA Announced Clearance To Maestro Brain Model Software ↗

August 09, 2022

ClearPoint Neuro (NASDAQ: CLPT) announced the U.S. Food and Drug Administration (FDA) 510(k) clearance to its Maestro Brain Model, intended for automatic labeling, visualization, volumetric and shape...

Via Benzinga

ClearPoint Neuro's Return On Capital Employed Insights ↗

June 15, 2022

According to data from Benzinga Pro, during Q1, ClearPoint Neuro's (NASDAQ:CLPT) reported sales totaled $5.03 million. Despite a 4.58% increase in earnings, the company posted a loss of $3.96 million.

Via Benzinga

Again, Buy ‘Em ↗

May 31, 2022

Today we discuss again why it’s time to start adding back risk. We cover the major breadth thrusts that fired, some great monthly charts, and more.

Via Talk Markets

38 Stocks Moving In Friday's Mid-Day Session ↗

May 20, 2022

Gainers Leju Holdings Limited (NYSE: LEJU) surged 27.8% to $4.0413.

Via Benzinga

66 Biggest Movers From Friday ↗

May 23, 2022

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.